---
title: SEQENS vs TriLink BioTechnologies
slug_a: seqens
slug_b: trilinkbiotech
site: cdmo
review_signal_gate: closed
canonical_path: /compare/seqens/trilinkbiotech
generated_by: BioBM Editorial AI
---

# SEQENS vs TriLink BioTechnologies

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

SEQENS (seqens) is listed for cdmo. Global CDMO and specialty ingredients manufacturer with 16 production sites and 9 R&D centres offering custom development and GMP manufacturing of pharmaceutical APIs, intermediates, and specialty chemicals from preclinical to commercial scale.

Services: 8. Modalities: 1. Indications: 0. Locations: 15. Certifications: 9. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in locations (15).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

TriLink BioTechnologies (trilinkbiotech) is listed for cdmo. TriLink manufactures mRNA, oligonucleotides, and modified nucleotides with proprietary CleanCap® capping technology achieving >95% Cap1 efficiency, supported by in-house analytical method development and a 118,000 sq ft GMP-capable facility.

Services: 6. Modalities: 2. Indications: 0. Locations: 1. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (6).

Review summary: Review summary withheld until site-level review gate opens.